Novavax headquarters in Gaithersburg, MD (Nathan Howard/Bloomberg via Getty Images)
August 8, 2023 03:33 PM EDT
Pharma
Coronavirus

No­vavax plans to have up­dat­ed Covid vac­cine to mar­ket by Sep­tem­ber — but will it be ready in time?

Paul Schloesser

Associate Editor

No­vavax is prepar­ing to have its XBB.1.5 Covid-19 vac­cine ready for mar­ket by the end of Sep­tem­ber, call­ing it its “high­est pri­or­i­ty.” How­ev­er, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times